Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Deals

Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics

Fineline Cube Dec 12, 2022

Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The...

Company Drug

Sino Biopharmaceutical’s ATR Kinase Inhibitor TCC1727 Accepted for FDA Review

Fineline Cube Dec 12, 2022

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced the acceptance for review of its Investigational New...

Company Deals

Acotec Scientific and Boston Scientific Enter Acquisition and Collaboration Agreement

Fineline Cube Dec 12, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) and US major Boston Scientific Corporation (NYSE: BSX)...

Company Drug

Biogen’s Aducanumab Administered to Chinese Patient for First Time

Fineline Cube Dec 12, 2022

US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a...

Company Drug

Stemirna Therapeutics’ COVID-19 mRNA Vaccine Gets EUA in Laos

Fineline Cube Dec 12, 2022

Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use...

Company Deals Digital

Medbanks Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 12, 2022

Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial...

Company Drug

Fujian Cosunter Completes Enrollment for Phase I Study of GST-HG171

Fineline Cube Dec 12, 2022

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of...

Company Drug

Alphamab Oncology Updates Clinical Studies for KN046 and KN026 at SABCS 2022

Fineline Cube Dec 12, 2022

China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at...

Company Deals

Roche and Zhongshan Hospital Collaborate on Clinical Studies and Innovation Center

Fineline Cube Dec 12, 2022

Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a...

Company Drug

ASH 2022: China Biotechs Showcase Latest Clinical Trial Results

Fineline Cube Dec 12, 2022

The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...

Company Deals R&D

Merck Partners with Tsinghua Shenzhen for Organoid 3D Printing System

Fineline Cube Dec 12, 2022

Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School,...

Company Deals

Luye Pharma Group Hands Over Seroquel Distribution Rights to DCH Auriga in Singapore

Fineline Cube Dec 12, 2022

China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to...

Company Drug

RemeGen’s RC118 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Fineline Cube Dec 9, 2022

China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained...

Company Drug

Innovent Biologics Presents Clinical Study Results at ESMO-IO 2022

Fineline Cube Dec 9, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the...

Policy / Regulatory

NMPA Extends Validation Period for COVID-19 Antigen Detection Reagents

Fineline Cube Dec 9, 2022

The National Medical Products Administration released a notification extending the validation period of approvals for...

Company Deals

Science Standard Medical Testing Raises Pre-Series A Funding

Fineline Cube Dec 9, 2022

Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens...

Company Deals

Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199

Fineline Cube Dec 9, 2022

Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...

Company Deals

XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development

Fineline Cube Dec 9, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...

Company Drug

Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma

Fineline Cube Dec 9, 2022

Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...

Company Deals

Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer

Fineline Cube Dec 9, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...

Posts pagination

1 … 639 640 641 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.